RT Journal Article
SR Electronic
T1 Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.21.20248640
DO 10.1101/2020.12.21.20248640
A1 Tegally, Houriiyah
A1 Wilkinson, Eduan
A1 Giovanetti, Marta
A1 Iranzadeh, Arash
A1 Fonseca, Vagner
A1 Giandhari, Jennifer
A1 Doolabh, Deelan
A1 Pillay, Sureshnee
A1 San, Emmanuel James
A1 Msomi, Nokukhanya
A1 Mlisana, Koleka
A1 von Gottberg, Anne
A1 Walaza, Sibongile
A1 Allam, Mushal
A1 Ismail, Arshad
A1 Mohale, Thabo
A1 Glass, Allison J
A1 Engelbrecht, Susan
A1 Van Zyl, Gert
A1 Preiser, Wolfgang
A1 Petruccione, Francesco
A1 Sigal, Alex
A1 Hardie, Diana
A1 Marais, Gert
A1 Hsiao, Marvin
A1 Korsman, Stephen
A1 Davies, Mary-Ann
A1 Tyers, Lynn
A1 Mudau, Innocent
A1 York, Denis
A1 Maslo, Caroline
A1 Goedhals, Dominique
A1 Abrahams, Shareef
A1 Laguda-Akingba, Oluwakemi
A1 Alisoltani-Dehkordi, Arghavan
A1 Godzik, Adam
A1 Wibmer, Constantinos Kurt
A1 Sewell, Bryan Trevor
A1 Lourenço, José
A1 Alcantara, Luiz Carlos Junior
A1 Pond, Sergei L Kosakovsky
A1 Weaver, Steven
A1 Martin, Darren
A1 Lessells, Richard J
A1 Bhiman, Jinal N
A1 Williamson, Carolyn
A1 de Oliveira, Tulio
YR 2020
UL http://medrxiv.org/content/early/2020/12/22/2020.12.21.20248640.abstract
AB Continued uncontrolled transmission of the severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in many parts of the world is creating the conditions for significant virus evolution. Here, we describe a new SARS-CoV-2 lineage (501Y.V2) characterised by eight lineage-defining mutations in the spike protein, including three at important residues in the receptor-binding domain (K417N, E484K and N501Y) that may have functional significance. This lineage emerged in South Africa after the first epidemic wave in a severely affected metropolitan area, Nelson Mandela Bay, located on the coast of the Eastern Cape Province. This lineage spread rapidly, becoming within weeks the dominant lineage in the Eastern Cape and Western Cape Provinces. Whilst the full significance of the mutations is yet to be determined, the genomic data, showing the rapid displacement of other lineages, suggest that this lineage may be associated with increased transmissibility.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.krisp.org.za/ngs-sa/ Funding StatementThis research reported in this publication was supported by the Strategic Health Innovation Partnerships Unit of the South African Medical Research Council, with funds received from the South African Department of Science and Innovation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The project was approved by University of KwaZulu-Natal Biomedical Research Ethics Committee. Protocol reference number: BREC/00001510/2020. Project title: Spatial and genomic monitoring of COVID-19 cases in South Africa. This project was also approved by University of the Witwatersrand Human Research Ethics Committee. Clearance certificate number: M180832. Project title: Surveillance for outpatient influenza-like illness and asymptomatic virus colonization in South Africa. Sequence data from the Western Cape was approved by the Stellenbosch University HREC Reference No: N20/04/008_COVID-19. Project Title: COVID-19: sequencing the virus from South African patients.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data has been deposited in GISAID